http://www.novartis.com 2008-07-17T07:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2008/1236488.shtml

First-half results for continuing operations led by improving Pharmaceuticals performance ahead of expectations and expansion in Vaccines and Diagnostics

Net sales rise 11% (+2% in local currencies) to USD 20.6 billion

Operating income advances 12% to USD 4.9 billion on business expansion, productivity gains and currency benefits

Net income up 13% to USD 4.6 billion; basic EPS rises 17% to USD 2.01

Dynamic growth from new products - including Tekturna/Rasilez, Exforge, Lucentis, Exelon Patch and Aclasta/Reclast - provides USD 1.3 billion in first-half net sales

Key R&D projects on track for 2008 submissions, particularly Afinitor (RAD001) for advanced kidney cancer and Menveo meningococcal meningitis vaccine

25% stake in Alcon, the world leader in eye care, purchased in July; strategic acquisitions strengthen portfolio and complement internal growth drivers

Novartis on track for record sales and earnings in 2008 from continuing operations

]]> 2008-07-11T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2008/1235238.shtml

Alliance enables Novartis to rapidly scale up development and production for rich biological pipeline, which accounts for a quarter of its development portfolio

Strong Novartis R&D capabilities coupled with Lonza's leadership in process development and manufacturing, provides ideal long-term partnership

]]> 2008-07-10T07:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2008/1234914.shtml

Novartis and Speedel have a long-standing collaboration based on financial support for Speedel creation in 1998 and development of Tekturna/Rasilez

Speedel pipeline provides access to many R&D projects targeting cardiovascular disease, including a range of direct renin inhibitors

Ownership of Speedel provides greater flexibility and speed in development of Tekturna/Rasilez and also ends royalty and manufacturing fee payments

After acquiring a 51.7% stake directly from major Speedel shareholders for CHF 130 per share in cash, Novartis now holds 61.4% of Speedel

Novartis will commence a mandatory tender offer to acquire the remaining Speedel shares at the same price

]]> 2008-07-08T07:30:00 CET http://www.novartis.com/newsroom/media-releases/en/2008/1234280.shtml

Strong strategic fit with Novartis thanks to Alcon's pharmaceutical, surgical and consumer eye care products businesses

]]> 2008-07-02T01:16:00 CET http://www.novartis.com/newsroom/media-releases/en/2008/1232992.shtml

Jury verdict in Montgomery County Circuit Court awards $33 million in compensatory damages

Jury decides in favor of Novartis and rejects claims for punitive damages

NPC maintains it reported true and accurate prices and will file appeal

]]> 2008-06-24T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2008/1230343.shtml

The NITD and the TB Alliance's collaboration aims to move projects quickly from the research phase through the translational stage and into development

Both partners will leverage their broad networks of expertise and resources to rapidly bring effective, simpler treatments to patients

]]> 2008-06-17T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2008/1228485.shtml

Novartis to study organ protection potential of Rasilez beyond documented ability to provide powerful blood pressure reductions that last beyond 24 hours[1],[2]

Three megatrials explore Rasilez benefits in difficult-to-treat patients with life-threatening co-morbidities - heart failure, cardiovascular events in elderly and diabetic kidney disease

Data presented at "Hypertension 2008" congress highlight impressive efficacy of Rasilez in managing high blood pressure in elderly, the fastest growing patient demographic segment with climbing healthcare costs[3],[4],[5]

]]> 2008-06-13T07:30:00 CET http://www.novartis.com/newsroom/media-releases/en/2008/1227552.shtml

Efficacy and safety profile in large randomized Phase III study consistent with landmark IRIS trial, which established Glivec as standard of care

Study did not meet primary endpoint at 1 year, yet shows faster time to molecular responses with 800 vs. 400 mg dose

Findings reinforce that monitoring blood levels of Glivec may help optimize treatment benefit for individual patients

Novartis committed to improving first-line treatment through additional study follow-up and completing enrollment to Tasigna vs. Glivec trial

]]> 2008-06-12T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2008/1227249.shtml

Conditional offer made by TRC Capital Corporation for up to two million Novartis American Depositary Shares

Novartis recommends against shareholders tendering their shares in response to TRC Capital's unsolicited mini-tender offer

]]> 2008-06-10T20:07:52 CET http://www.novartis.com/newsroom/media-releases/en/2008/1226826.shtml

First bond offering ever by Novartis in Swiss francs sees very strong demand and ranks as the largest-ever corporate offering in the Swiss franc market

Two benchmark bonds offered - a domestic seven-year bond and a four-year bond in the international market segment

]]>